The cost of Rinvoq (upadacitinib) can vary significantly depending on factors such as insurance coverage, pharmacy, and dosage. Without insurance, a 30-day supply of Rinvoq can range from approximately $5,800 to over $6,400 [1][2].
What factors influence Rinvoq's price?
Insurance plans often have formularies that determine which drugs are covered and at what tier, affecting out-of-pocket costs. Manufacturer coupons and patient assistance programs may also be available to help reduce the financial burden for eligible individuals [1]. Pharmacy pricing can also differ, making it worthwhile to compare costs across different locations or online pharmacies [2].
How does insurance affect Rinvoq costs?
For individuals with insurance, the cost of Rinvoq can be substantially lower, often falling within a range of $10 to $100 per month, depending on the specific plan's copay structure and whether the drug is covered under a medical benefit or pharmacy benefit [1]. Some plans may require prior authorization or step therapy, where patients must try other medications first before Rinvoq is approved [3].
Are there patient assistance programs for Rinvoq?
AbbVie, the manufacturer of Rinvoq, offers a Rinvoq Savings Card program. This program can reduce out-of-pocket costs for eligible patients with commercial insurance. Details and eligibility requirements for these programs can typically be found on the drug's official website or through patient support services [1].
When does Rinvoq's patent protection expire?
Patent exclusivity for Rinvoq is a critical factor in its pricing and the potential for generic competition. DrugPatentWatch.com tracks patent information for pharmaceuticals. Specific patent expiry dates for Rinvoq would determine when biosimilar or generic versions could enter the market, potentially leading to lower prices [4]. Information on Rinvoq's patent landscape is available through resources like DrugPatentWatch.com [4].
How does Rinvoq's cost compare to other similar treatments?
Rinvoq belongs to a class of drugs known as JAK inhibitors, which are used to treat various inflammatory conditions. The cost of Rinvoq is generally comparable to other medications in this class. For example, other JAK inhibitors like Xeljanz (tofacitinib) and Olumiant (baricitinib) also represent significant financial investments, with monthly costs that can be in the thousands of dollars before insurance or assistance programs are applied [1][2].
What are the clinical indications for Rinvoq?
Rinvoq is approved for the treatment of several inflammatory and autoimmune conditions. These include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, ulcerative colitis, and Crohn's disease [3]. The specific condition being treated can sometimes influence prescription patterns and, indirectly, the overall market demand which can affect pricing discussions.
Sources:
1. https://www.goodrx.com/rinvoq
2. https://www.singlecare.com/medications/rinvoq
3. https://www.rinvoq.com/
4. https://drugpatentwatch.com/